Directly to content
  1. Publishing |
  2. Search |
  3. Browse |
  4. Recent items rss |
  5. Open Access |
  6. Jur. Issues |
  7. DeutschClear Cookie - decide language by browser settings

Intensity-modulated radiotherapy with integrated-boost in patients with bone metastasis of the spine: study protocol for a randomized controlled trial

Sprave, Tanja ; Welte, Stefan Ezechiel ; Bruckner, Thomas ; Förster, Robert ; Bostel, Tilman ; Schlampp, Ingmar ; Nicolay, Nils Henrik ; Debus, Jürgen ; Rief, Harald

In: Trials, 19 (2018), Nr. 59. pp. 1-6. ISSN 1468-6694

[thumbnail of 13063_2018_Article_2452.pdf]
Preview
PDF, English
Download (500kB) | Lizenz: Creative Commons LizenzvertragIntensity-modulated radiotherapy with integrated-boost in patients with bone metastasis of the spine: study protocol for a randomized controlled trial by Sprave, Tanja ; Welte, Stefan Ezechiel ; Bruckner, Thomas ; Förster, Robert ; Bostel, Tilman ; Schlampp, Ingmar ; Nicolay, Nils Henrik ; Debus, Jürgen ; Rief, Harald underlies the terms of Creative Commons Attribution 4.0

Citation of documents: Please do not cite the URL that is displayed in your browser location input, instead use the DOI, URN or the persistent URL below, as we can guarantee their long-time accessibility.

Abstract

Background: Stereotactic body radiation therapy (SBRT) using intensity-modulated radiotherapy (IMRT) with dose escalation by simultaneous integrated boost (SIB) can be a safe modality for treating spinal bone metastases with enhanced targeting accuracy and improve local tumor control.

Methods/Design: This is a single-center, prospective, randomized, controlled trial. One hundred and twenty patients with spinal bone metastases will receive palliative radiation therapy at the Heidelberg University Hospital. SBRT will be given in five or ten fractions with or without SIB. Four treatment arms are planned: IMRT with 30 Gy in ten fractions, IMRT with 30 Gy in ten fractions and SIB to 40 Gy, IMRT with 20 Gy in five fractions, and IMRT with 20 Gy in five fractions and SIB to 30Gy in five fractions will be compared. The target parameters will be measured at baseline level and at three and six months after radiation.

Discussion: The primary endpoint of this study was to assess and compare the local tumor control (by means of different fractionation schedules and biological doses to the tumor area). Secondary endpoints are acute and chronic adverse events, pain relief, quality of life, and fatigue.

Trial registration: ClinicalTrials.gov, NCT02832765 . Registered on 27 July 2016.

Document type: Article
Journal or Publication Title: Trials
Volume: 19
Number: 59
Publisher: BioMed Central
Place of Publication: London
Date Deposited: 30 Apr 2018 07:54
Date: 2018
ISSN: 1468-6694
Page Range: pp. 1-6
Faculties / Institutes: Medizinische Fakultät Heidelberg > Radiologische Universitätsklinik
Medizinische Fakultät Heidelberg > Institut für Medizinische Biometrie und Informatik
DDC-classification: 610 Medical sciences Medicine
About | FAQ | Contact | Imprint |
OA-LogoDINI certificate 2013Logo der Open-Archives-Initiative